Vinikoor MJSinkala EKanunga AMuchimba MNsokolo BChilengi RWandeler GMulenga JChisenga TBhattacharya DSaag MSFoster GFried MWKelly P2025-05-232018-Sep-210.4254/wjh.v10.i9.622https://pubs.cidrz.org/handle/123456789/10487AIM: To characterize antiviral therapy eligibility among hepatitis B virus (HBV)-infected adults at a university hospital in Zambia. METHODS: Hepatitis B surface antigen-positive adults ( RESULTS: The median age was 33 years, 71.9% were men, and 30.9% were diagnosed with HBV through a clinically-driven test with the remainder identified CONCLUSION: Approximately one in ten HBV-monoinfected Zambians were eligible for antivirals. Many had indeterminate phenotype and needed clinical follow-up.